2,735 Shares in Boston Scientific Co. (NYSE:BSX) Bought by Claro Advisors LLC

Claro Advisors LLC bought a new stake in Boston Scientific Co. (NYSE:BSX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 2,735 shares of the medical equipment provider's stock, valued at approximately $244,000.

Other institutional investors also recently modified their holdings of the company. Values First Advisors Inc. acquired a new position in Boston Scientific during the 3rd quarter worth approximately $28,000. Dunhill Financial LLC increased its holdings in shares of Boston Scientific by 86.4% during the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after buying an additional 152 shares in the last quarter. Global Wealth Strategies & Associates increased its holdings in shares of Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after buying an additional 250 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. acquired a new stake in shares of Boston Scientific during the 3rd quarter valued at $30,000. Finally, Capital Performance Advisors LLP acquired a new stake in shares of Boston Scientific during the 3rd quarter valued at $30,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Wall Street Analyst Weigh In

BSX has been the subject of several research reports. Needham & Company LLC reiterated a "hold" rating on shares of Boston Scientific in a research report on Wednesday, November 27th. TD Cowen raised their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a report on Thursday, December 12th. Sanford C. Bernstein boosted their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an "outperform" rating in a report on Thursday, October 24th. Canaccord Genuity Group raised their price target on shares of Boston Scientific from $98.00 to $101.00 and gave the company a "buy" rating in a research note on Monday, December 9th. Finally, BTIG Research lifted their price target on shares of Boston Scientific from $84.00 to $93.00 and gave the stock a "buy" rating in a report on Monday, October 14th. Three research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $97.26.

Boston Scientific Trading Up 1.3 %

Shares of NYSE:BSX traded up $1.26 during mid-day trading on Thursday, hitting $98.15. The company had a trading volume of 5,020,057 shares, compared to its average volume of 5,327,683. The company has a market capitalization of $144.65 billion, a PE ratio of 81.11, a price-to-earnings-growth ratio of 2.48 and a beta of 0.80. Boston Scientific Co. has a one year low of $59.85 and a one year high of $98.31. The firm has a fifty day moving average price of $90.57 and a 200 day moving average price of $84.23. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.04. The firm had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The business's quarterly revenue was up 19.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.50 earnings per share. As a group, research analysts forecast that Boston Scientific Co. will post 2.46 EPS for the current year.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the firm's stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the transaction, the executive vice president now directly owns 978 shares of the company's stock, valued at approximately $87,306.06. This trade represents a 93.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,877 shares of the business's stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the sale, the director now directly owns 39,398 shares of the company's stock, valued at approximately $3,610,038.74. The trade was a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,989 shares of company stock worth $2,702,261. Corporate insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.